Point-of-Care Glucose Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product Type (Accu Check Aviva Meter, Onetouch Verio Flex, i-STAT, Bayer CONTOUR Blood Glucose Monitoring System, Freestyle Lite, True Metrix, Accu-Chek Inform II, StatStrip, Others), By Region, and Competition, 2019-2029F
Published on: 2024-11-15 | No of Pages : 320 | Industry : Healthcare
Publisher : MIR | Format : PDF&Excel
Point-of-Care Glucose Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product Type (Accu Check Aviva Meter, Onetouch Verio Flex, i-STAT, Bayer CONTOUR Blood Glucose Monitoring System, Freestyle Lite, True Metrix, Accu-Chek Inform II, StatStrip, Others), By Region, and Competition, 2019-2029F
Forecast Period | 2025-2029 |
Market Size (2023) | USD 3.30 Billion |
CAGR (2024-2029) | 4.20% |
Fastest Growing Segment | Accu-Chek Inform II |
Largest Market | North America |
Market Size (2029) | USD 4.21 Billion |
Market Overview
Global Point-of-Care Glucose Testing Market was valued at USD 3.30 billion in 2023 and is anticipated to project steady growth in the forecast period with a CAGR of 4.20% through 2029. Point-of-Care Glucose Testing are the measurement of glucose levels in a patient's blood at the point of care, which can be a hospital, clinic, doctor's office, or even at home. This type of Monitor allows healthcare professionals and patients to quickly assess blood glucose levels without the need for sending samples to a central laboratory, which can lead to faster diagnosis and treatment decisions, particularly in cases of diabetes management. Point-of-Care Glucose Testing refers to the commercial landscape involving the products, devices, and services related to Point-of-Care Glucose Testing. This market encompasses a wide range of technologies, such as blood glucose meters, continuous glucose monitoring (CGM) systems, test strips, and other associated products. The market includes both professional use (healthcare providers conducting tests on patients) and self-monitoring by patients themselves.
Key Market Drivers
Increasing Prevalence of Diabetes Drives The Market Growth
The increasing prevalence of diabetes is a significant driver behind the growth of the global Point of Care Glucose Monitor (POCT) market. Diabetes is a chronic medical condition characterized by elevated blood glucose levels, and its rising prevalence has created a strong demand for effective and convenient glucose monitoring solutions. People with diabetes require regular monitoring of their blood glucose levels to manage the disease effectively. Monitoring helps them make informed decisions about diet, exercise, medication, and insulin dosages. Point-of-Care Glucose Testing provides a quick and convenient way to monitor blood glucose levels without the need for laboratory visits, making it easier for individuals to adhere to their monitoring regimen. Early detection of diabetes and prediabetes is crucial for preventing complications and managing the disease.
As the prevalence of diabetes increases, there is a greater emphasis on early diagnosis and intervention to prevent or delay the onset of complications such as cardiovascular diseases, kidney problems, and nerve damage. Point-of-Care Glucose Testing enables timely detection and intervention, leading to better outcomes for patients. With the increasing prevalence of diabetes, there is a growing focus on patient empowerment and self-management. Point-of-Care Glucose Testing empowers individuals with diabetes to take control of their health by enabling them to monitor their blood glucose levels at home or on the go. This empowerment promotes better engagement in self-care and treatment adherence. The economic burden of diabetes is substantial, with costs associated with medical care, hospitalization, medications, and complications. Healthcare systems are seeking cost-effective solutions to manage diabetes. Point-of-Care Glucose Testing can help reduce costs by minimizing the need for frequent laboratory Monitor and hospital admissions, leading to more efficient resource utilization.
Increasing Demand for Immediate Results
The increasing demand for immediate results is a significant driver behind the growth of the global Point of Care Glucose Monitor (POCT) market. In various healthcare settings, the ability to obtain rapid test results has become a crucial factor for effective patient care and decision-making. For patients with diabetes, prompt adjustments to medication, insulin dosages, and dietary choices are essential for maintaining optimal blood glucose levels. Point-of-Care Glucose Testing provides immediate results, enabling healthcare providers to make real-time decisions about treatment modifications during patient visits. This timely response helps prevent hyperglycemia, hypoglycemia, and associated complications. In emergency departments and critical care units, quick access to diagnostic information is crucial for assessing patients' conditions and determining appropriate interventions. Point-of-Care Glucose Testing allows healthcare professionals to rapidly assess glucose levels in patients who may be in critical conditions, ensuring timely and appropriate care.
In outpatient settings, primary care clinics, and specialty clinics, healthcare providers often need to make rapid clinical decisions based on test results. Point-of-Care Glucose Testing provides immediate data, allowing clinicians to make informed decisions about treatment plans, medication adjustments, and referrals to specialists. Patients value convenience in healthcare. Immediate test results provided by Point-of-Care Glucose Testing reduce waiting times and the need for follow-up appointments solely for test result discussions. This convenience enhances the patient experience and encourages regular monitoring and engagement in their own care. Point-of-Care Glucose Testing streamlines clinical workflows by eliminating the need to send samples to central laboratories and wait for results. This efficiency benefits both patients and healthcare providers, leading to improved resource utilization and patient throughput. Rapid access to glucose test results helps prevent diabetes-related complications. Healthcare providers can identify glucose fluctuations quickly and intervene to avoid dangerous situations such as hypoglycemic episodes, which can lead to unconsciousness or even death.
Aging Population Drive the Market Growth
The aging population is a significant driver behind the growth of the Point of Care Glucose Monitor (POCT) market. As the global population continues to age, there is a higher prevalence of chronic conditions such as diabetes, which necessitates more frequent and convenient monitoring of blood glucose levels. The aging process is often associated with an increased risk of developing chronic diseases, including type 2 diabetes. Older individuals are more susceptible to insulin resistance and other factors that contribute to elevated blood glucose levels. This results in a higher prevalence of diabetes among the elderly population. Older adults frequently have multiple health conditions that require ongoing management. Diabetes management becomes more complex when combined with other conditions such as hypertension, cardiovascular disease, and kidney problems. Point-of-Care Glucose Testing offers a convenient way to monitor glucose levels, making it easier to integrate diabetes management into the overall care plan.
Healthcare systems are placing greater emphasis on preventive care and early intervention to manage chronic conditions and prevent complications. Point-of-Care Glucose Testing aligns with this approach, allowing healthcare providers to monitor blood glucose levels in older adults and intervene promptly to prevent adverse outcomes. Older adults may experience rapid fluctuations in blood glucose levels due to factors such as medications, changes in diet, and reduced physical activity. Point-of-Care Glucose Testing provides immediate results, enabling healthcare professionals to make timely adjustments to medications and treatment plans to maintain stable glucose levels. Many elderly individuals are on multiple medications. Some medications can impact blood glucose levels, and monitoring glucose levels becomes essential to ensure that medication regimens are well-adjusted and safe for older patients.
Key Market Challenges
Accuracy and Precision
Accuracy and precision are crucial factors in the effectiveness of glucose Monitor, particularly in the Point of Care Glucose Monitor (POCT) market. Inaccurate or imprecise glucose measurements can lead to incorrect treatment decisions, compromised patient safety, and unreliable data for diabetes management. Inaccurate glucose measurements can lead to improper treatment decisions, such as incorrect insulin dosages. This can result in hypoglycemia (low blood sugar) or hyperglycemia (high blood sugar), both of which can have serious health consequences, including loss of consciousness or diabetic ketoacidosis. Healthcare providers rely on accurate glucose measurements to make informed treatment decisions. Inaccurate readings can lead to inappropriate adjustments in medication, insulin therapy, or diet, potentially affecting patients' overall health and diabetes management. Inaccurate glucose measurements can lead to suboptimal glycemic control, which is associated with increased risks of diabetes-related complications such as cardiovascular diseases, kidney problems, and neuropathy.
User Training and Proficiency
User training and proficiency are critical challenges in the Global Point of Care Glucose Monitor (POCT) market. The accurate and effective use of glucose Monitor devices relies heavily on proper training and user proficiency. Insufficient training can lead to inaccurate readings, misinterpretation of results, and compromised diabetes management. Improper device usage due to lack of training can lead to inaccurate glucose measurements. Users may not follow proper Monitor procedures, leading to errors in obtaining blood samples or incorrect handling of Monitor strips, which can affect the reliability of results. Users who lack proper training may not consistently perform glucose tests as recommended. Inconsistent Monitor practices can lead to gaps in monitoring, hindering the effectiveness of diabetes management plans. Interpreting glucose test results correctly is crucial for making informed treatment decisions. Inadequate training can lead to misinterpretation of results, resulting in inappropriate adjustments to medication, insulin dosages, or lifestyle behaviors.
Quality Control and Maintenance
Quality control and maintenance are critical challenges in the Global Point of Care Glucose Monitor (POCT) market. Ensuring the ongoing accuracy and reliability of glucose Monitor devices is essential for effective diabetes management. Without proper quality control and maintenance, devices may produce inaccurate readings, leading to incorrect treatment decisions and compromised patient safety. Over time, Point-of-Care Glucose Testing devices can experience wear and tear that affects their performance. Inadequate maintenance and regular use can lead to device degradation, resulting in inaccurate readings. Point-of-Care Glucose Testing devices require regular calibration to maintain accuracy. Without proper calibration, the readings can drift from the true values, leading to incorrect treatment decisions. Improper cleaning, handling, or storage by users can introduce errors and contaminants into the Monitor process. Regular quality control measures and maintenance practices are necessary to mitigate the impact of user errors. Contaminants from blood samples or external sources can affect the accuracy of glucose measurements. Quality control measures are essential to identify and address contamination issues. Environmental conditions such as temperature and humidity can impact the performance of glucose Monitor devices. Without proper maintenance, these factors can contribute to inaccuracies.
Key Market Trends
Rise of Continuous Glucose Monitoring (CGM)
The rise of Continuous Glucose Monitoring (CGM) is a significant trend in the Global Point of Care Glucose Monitor (POCT) market, offering a new paradigm for diabetes management. CGM systems have gained popularity due to their ability to provide real-time, continuous data on glucose levels, enabling more proactive and personalized diabetes care.
CGM data provides insights into how diet, exercise, medication, and other factors affect glucose levels, enabling more personalized treatment adjustments and lifestyle modifications. CGM data can guide healthcare providers in making informed decisions about insulin dosing, medication regimens, and overall diabetes management strategies. The real-time nature of CGM data engages patients in their own care, encouraging them to make timely adjustments and better manage their glucose levels. CGM systems help reduce the frequency and severity of hypoglycemic and hyperglycemic events by providing early warnings and insights into glucose trends. CGM is particularly beneficial for children and older adults who may have difficulty with frequent fingerstick Monitor. CGM systems offer caregivers and parents continuous insight into glucose levels.
Segmental Insights
Product Type
The system often includes data management features that allow healthcare providers to track and analyse glucose trends over time, contributing to better diabetes management. Accu-Chek Inform II is commonly used in hospital and clinical settings, where immediate glucose monitoring is crucial for patient care. Its integration with hospital information systems enhances workflow efficiency. The Accu-Chek Inform II system have been clinically validated and supported by research, further establishing its credibility and trustworthiness among healthcare professionals.
Regional Insights
The North America region has emerged as the frontrunner in the global point-of-care glucose testing market, solidifying its position through a combination of advanced healthcare infrastructure, extensive research facilities, and a steadfast commitment to patient well-being. Particularly in the United States and Canada, the healthcare landscape is characterized by state-of-the-art medical facilities, renowned research institutions, and a robust emphasis on delivering high-quality care to individuals. This conducive environment has facilitated the widespread adoption and utilization of point-of-care glucose testing devices, which play a crucial role in managing diabetes, a condition with a significant prevalence rate across North America. With diabetes being a prevalent health concern in the region, there is a pressing need for effective glucose monitoring solutions, making point-of-care glucose testing devices indispensable tools in healthcare settings.
North America boasts a high level of awareness regarding the importance of regular glucose monitoring and diabetes management, both among healthcare professionals and patients. This heightened awareness has translated into increased acceptance and utilization of point-of-care glucose testing devices as essential components of diabetes care protocols. The region serves as a hotbed for technological innovation, particularly in the realm of medical device development. Numerous companies in North America are at the forefront of creating cutting-edge point-of-care glucose testing devices that prioritize accuracy, convenience, and user-friendly features. This ongoing innovation drives the evolution of glucose monitoring technology, ensuring that patients have access to the most advanced and effective tools for managing their health.
Recent Developments
- In March 2024, Dexcom unveiled its latest Continuous Glucose Monitoring (CGM) system, Dexcom ONE+, in Ireland. Harnessing the renowned accuracy of Dexcom's sensor design, Dexcom ONE+ is specifically designed for people managing various types of diabetes. Developed based on feedback from both end-users and healthcare professionals (HCPs), Dexcom ONE+ represents the latest addition to Dexcom's CGM portfolio, now available to individuals with all forms of diabetes in Ireland. Ranging from the advanced capabilities of Dexcom G6 and G7, which are beneficial for managing the health of high-risk populations and supporting Hybrid Closed Loop systems (HCL), to the user-friendly and adaptable Dexcom ONE+, Dexcom's CGM lineup is supported by extensive clinical research and data, establishing it as a trusted option among individuals living with diabetes.
Key Market Players
- F.Hoffmann-La Roche Ltd
- Abbott Laboratories Inc.
- Nipro Corporation
- Lifescan, Inc.
- Nova Biomedical Corporation
- ACON Laboratories Inc.
- Trividia Health, Inc.
- Prodigy Diabetes Care, LLC
- Ascensia Diabetes CareHoldings AG
- EKF Diagnostics Holdings PLC
By Product Type | By Region |
|
|